The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Open accessAbstract
Purpose: Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in cancer patients with chronic HBV (hepatitis B surface antigen [HBsAg] positive) undergoing cytotoxic chemotherapy. In patients who have resolved HBV (HBsAg negative and antibody to hepatitis B core antigen [anti-HBc] ± antibody to hepatitis B surface antigen [anti-HBs] positive), such incidence has been much less common until recent use of rituximab. In this study on HBsAg-negative/anti-HBc–positive lymphoma patients, the objectives were to determine the HBV reactivation rate in patients treated with rituximab-containing chemotherapy and to compare it with the rate in patients treated without rituximab. Patients and Methods: Between January 2003 and December 2006, all patients diagnosed with CD20+ diffuse large B-cell lymphoma (DLBCL) had HBsAg determined before anticancer therapy. They were treated with either cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone or rituximab plus CHOP (R-CHOP). HBsAg-negative patients had anti-HBc determined; serum was stored for anti-HBs and HBV DNA. All patients were observed for HBV reactivation, which was defined as detectable HBV DNA with ALT elevation during and for 6 months after anticancer therapy. Results: Among 104 CD20+ DLBCL patients, 80 were HBsAg negative. Of the latter, 46 patients (44.2%) were HBsAg negative/anti-HBc positive; 25 of these patients were treated with CHOP, and none had HBV reactivation. In contrast, among the 21 patients treated with R-CHOP, five developed HBV reactivation, including one patient who died of hepatic failure (P = .0148). Exploratory analysis identified male sex, absence of anti-HBs, and use of rituximab to be predictive of HBV reactivation. Conclusion: Among HBsAg-negative/anti-HBc–positive DLBCL patients treated with R-CHOP, 25% developed HBV reactivation. Close monitoring until at least 6 months after anticancer therapy is required, with an alternative approach of prophylactic antiviral therapy to prevent this potentially fatal condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Hepatitis B Virus Infection — Natural History and Clinical Consequences
Ganem, D., & Prince, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031087 · Cited by 2,357
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Rehermann, B., Ferrari, C., Pasquinelli, C., & Chisari, F. V. (1996) · Nature Medicine · doi:10.1038/nm1096-1104 · Cited by 854
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
Lok, A. S. F., Liang, R. H. S., Chiu, E. K. W., Wong, K.-L., Chan, T.-K., & Todd, D. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90599-g · Cited by 827
Self-citationYeo, W., Chan, P. K. S., Zhong, S., Ho, W. M., Steinberg, J. L., Tam, J. S., Hui, P., Leung, N. W. Y., Zee, B., & Johnson, P. J. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0 · Cited by 627
Self-citationOsterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Yeo, W., Zee, B., Zhong, S., Chan, P. K. S., Wong, W.-L., Ho, W. M., Lam, K. C., & Johnson, P. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601699 · Cited by 312
Self-citation
Cited by
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationReddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.039 · Cited by 861
Therapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Perrillo, R. P., Gish, R., & Falck-Ytter, Y. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.038 · Cited by 504
Seto, W.-K., Chan, T. S. Y., Hwang, Y.-Y., Wong, D. K.-H., Fung, J., Liu, K. S.-H., Gill, H., Lam, Y.-F., Lie, A. K. W., Lai, C.-L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7081 · Cited by 332
Self-citationHuang, Y.-H., Hsiao, L.-T., Hong, Y.-C., Chiou, T.-J., Yu, Y.-B., Gau, J.-P., Liu, C.-Y., Yang, M.-H., Tzeng, C.-H., Lee, P.-C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5938 · Cited by 326
Hsu, C., Tsou, H.-H., Lin, S.-J., Wang, M.-C., Yao, M., Hwang, W.-L., Kao, W.-Y., Chiu, C.-F., Lin, S.-F., Lin, J., et al. (2014) · Hepatology · doi:10.1002/hep.26718 · Cited by 277
Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283309 · Cited by 266
Muchtar, E., Magen, H., & Gertz, M. A. (2017) · Blood · doi:10.1182/blood-2016-09-719773 · Cited by 190
Zhang, X., Zhou, Y., Chen, C., Fang, W., Cai, X., Zhang, X., Zhao, M., Zhang, B., Jiang, W., Lin, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0808-5 · Cited by 185
Lau, G., Yu, M.-L., Wong, G., Thompson, A., Ghazinian, H., Hou, J.-L., Piratvisuth, T., Jia, J.-D., Mizokami, M., Cheng, G., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10239-x · Cited by 180
Self-citation
Metadata
- Authors
- Yeo, W., Chan, T. C., Leung, N. W. Y., Lam, W. Y., Mo, F. K. F., Chu, M. T., Chan, H. L. Y., Hui, E. P., Lei, K. I. K., Mok, T. S. K., & Chan, P. K. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-01
- Volume
- 27
- Issue
- 4
- Pages
- 605-611
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161758234
- Cited by
- 636
- References
- 20
- FWCI
- 33.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.